nach oben

NeuroMolecular Medicine

Erschienen in:

07.07.2020 | Original Paper

A Tellurium-Based Small Immunomodulatory Molecule Ameliorates Depression-Like Behavior in Two Distinct Rat Models

verfasst von: Moshe Hagar, Gersner Roman, Okun Eitan, Barnea-Ygael Noam, Zangen Abrham, Sredni Benjamin

Erschienen in: NeuroMolecular Medicine | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Abstract

Major depressive disorder (MDD) is a leading cause of morbidity, and the fourth leading cause of disease burden worldwide. While MDD is a treatable condition for many individuals, others suffer from treatment-resistant depression (TRD). Here, we suggest the immunomodulatory compound AS101 as novel therapeutic alternative. We previously showed in animal models that AS101 reduces anxiety-like behavior and elevates levels of the brain-derived neurotrophic factor (BDNF), a protein that has a key role in the pathophysiology of depression. To explore the potential antidepressant properties of AS101, we used the extensively characterized chronic mild stress (CMS) model, and the depressive rat line (DRL Finally, in Exp. 3 to attain insight into the mechanism we knocked down BDNF in the hippocampus, and demonstrated that the beneficial effect of AS101 was abrogated. Together with the previously established safety profile of AS101 in humans, these results may represent the first step towards the development of a novel treatment option for MDD and TRD.

Nur mit Berechtigung zugänglich

Adachi, M., Barrot, M., Autry, A. E., Theobald, D., & Monteggia, L. M. (2008). Selective loss of brain-derived neurotrophic factor in the dentate gyrus attenuates antidepressant efficacy. Biological Psychiatry, 63(7), 642–649.CrossRef

Akiskal, H. S. (2000). Temperament and mood disorders. Harvard Mental Health Letter, 16(8), 5–6.PubMed

Bajkowska, M., Branski, P., Smialowska, M., & Pilc, A. (1999). Effect of chronic antidepressant or electroconvulsive shock treatment on mGLuR1a immunoreactivity expression in the rat hippocampus. Polish Journal of Pharmacology, 51(6), 539–541.PubMed

Baker-Herman, T. L., Fuller, D. D., Bavis, R. W., Zabka, A. G., Golder, F. J., Doperalski, N. J., et al. (2004). BDNF is necessary and sufficient for spinal respiratory plasticity following intermittent hypoxia. Nature Neuroscience, 7(1), 48–55.CrossRef

Bakunina, N., Pariante, C. M., & Zunszain, P. A. (2015). Immune mechanisms linked to depression via oxidative stress and neuroprogression. Immunology, 144(3), 365–373.CrossRef

Balu, D. T., Hoshaw, B. A., Malberg, J. E., Rosenzweig-Lipson, S., Schechter, L. E., & Lucki, I. (2008). Differential regulation of central BDNF protein levels by antidepressant and non-antidepressant drug treatments. Brain Research, 1211, 37–43.CrossRef

Bing, S. J., Shemesh, I., Chong, W. P., Horai, R., Jittayasothorn, Y., Silver, P. B., et al. (2019). AS101 ameliorates experimental autoimmune uveitis by regulating Th1 and Th17 responses and inducing Treg cells. Journal of autoimmunity. https://doi.org/10.1016/j.jaut.2019.02.006.CrossRefPubMedPubMedCentral

Boldrini, M., Galfalvy, H., Dwork, A. J., Rosoklija, G. B., Trencevska-Ivanovska, I., Pavlovski, G., et al. (2019). Resilience is associated with larger dentate gyrus while suicide decedents with major depressive disorder have fewer granule neurons. Biological Psychiatry. https://doi.org/10.1016/j.biopsych.2018.12.022.CrossRefPubMedPubMedCentral

Castrén, E., & Rantamäki, T. (2010). The role of BDNF and its receptors in depression and antidepressant drug action: reactivation of developmental plasticity. Developmental Neurobiology, 70(5), 289–297.CrossRef

Czeh, B., Fuchs, E., Wiborg, O., & Simon, M. (2016). Animal models of major depression and their clinical implications. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 64, 293–310. https://doi.org/10.1016/j.pnpbp.2015.04.004.CrossRef

Dailly, E., Chenu, F., Renard, C. E., & Bourin, M. (2004). Dopamine, depression and antidepressants. Fundamental & Clinical Pharmacology, 18(6), 601–607.CrossRef

de Sousa, R. T., Zanetti, M. V., Brunoni, A. R., & Machado-Vieira, R. (2015). Challenging treatment-resistant major depressive disorder: A roadmap for improved therapeutics. Current Neuropharmacology, 13(5), 616–635.CrossRef

Diniz, C., Casarotto, P. C., Resstel, L., & Joca, S. R. L. (2018). Beyond good and evil: A putative continuum-sorting hypothesis for the functional role of proBDNF/BDNF-propeptide/mBDNF in antidepressant treatment. Neuroscience & Biobehavioral Reviews, 90, 70–83. https://doi.org/10.1016/j.neubiorev.2018.04.001.CrossRef

Duman, R. S., & Li, N. (2012). A neurotrophic hypothesis of depression: role of synaptogenesis in the actions of NMDA receptor antagonists. Philosophical Transactions of the Royal Society B: Biological Sciences, 367(1601), 2475–2484.CrossRef

Duman, R. S., & Monteggia, L. M. (2006). A neurotrophic model for stress-related mood disorders. Biological Psychiatry, 59(12), 1116–1127.CrossRef

Elvsåshagen, T., Zuzarte, P., Westlye, L. T., Bøen, E., Josefsen, D., Boye, B., et al. (2016). Dentate gyrus-cornu ammonis (CA) 4 volume is decreased and associated with depressive episodes and lipid peroxidation in bipolar II disorder: Longitudinal and cross-sectional analyses. Bipolar Disorders, 18(8), 657–668.CrossRef

Enomoto, S., Shimizu, K., Nibuya, M., Suzuki, E., Nagata, K., & Kondo, T. (2017). Activated brain-derived neurotrophic factor/TrkB signaling in rat dorsal and ventral hippocampi following 10-day electroconvulsive seizure treatment. Neuroscience Letters, 660, 45–50.CrossRef

Fava, M., & Kendler, K. S. (2000). Major depressive disorder. Neuron, 28(2), 335–341.CrossRef

Gersner, R., Dar, D. E., Shabat-Simon, M., & Zangen, A. (2005). Behavioral analysis during the forced swimming test using a joystick device. Journal of Neuroscience Methods, 143(2), 117–121. https://doi.org/10.1016/j.jneumeth.2004.09.017.CrossRefPubMed

Gersner, R., Gal, R., Levit, O., Moshe, H., & Zangen, A. (2014). Inherited behaviors, BDNF expression and response to treatment in a novel multifactorial rat model for depression. International Journal of Neuropsychopharmacology, 17(6), 945–955. https://doi.org/10.1017/S1461145714000030.CrossRefPubMed

Gersner, R., Gordon-Kiwkowitz, M., & Zangen, A. (2009). Automated behavioral analysis of limbs' activity in the forced swim test. Journal of Neuroscience Methods, 180(1), 82–86.CrossRef

Gersner, R., Toth, E., Isserles, M., & Zangen, A. (2010). Site-specific antidepressant effects of repeated subconvulsive electrical stimulation: potential role of brain-derived neurotrophic factor. Biological Psychiatry, 67(2), 125–132. https://doi.org/10.1016/j.biopsych.2009.09.015.CrossRefPubMed

Gross, M., Stanciu, E., Kenigsbuch-Sredni, D., Sredni, B., & Pinhasov, A. (2017). The immunomodulatory tellurium compound ammonium trichloro (dioxoethylene-O, O′) tellurate reduces anxiety-like behavior and corticosterone levels of submissive mice. Behavioural Pharmacology, 28(6), 458–465. https://doi.org/10.1097/FBP.0000000000000319.CrossRefPubMed

Gulyaeva, N. V. (2018). Functional neurochemistry of the ventral and dorsal hippocampus: stress, depression, dementia and remote hippocampal damage. Neurochemical Research. https://doi.org/10.1007/s11064-018-2662-0.CrossRefPubMed

Halbach, O. B. U., & Halbach, V. B. U. (2018). BDNF effects on dendritic spine morphology and hippocampal function. Cell and Tissue Research, 373(3), 729–741.CrossRef

Kallmunzer, B., Volbers, B., Karthaus, A., Tektas, O. Y., Kornhuber, J., & Muller, H. H. (2016). Treatment escalation in patients not responding to pharmacotherapy, psychotherapy, and electro-convulsive therapy: experiences from a novel regimen using intravenous S-ketamine as add-on therapy in treatment-resistant depression. Journal of Neural Transmission (Vienna), 123(5), 549–552. https://doi.org/10.1007/s00702-015-1500-7.CrossRef

Kubera, M., Obuchowicz, E., Goehler, L., Brzeszcz, J., & Maes, M. (2011). In animal models, psychosocial stress-induced (neuro) inflammation, apoptosis and reduced neurogenesis are associated to the onset of depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 35(3), 744–759.CrossRef

Lewitus, G. M., Wilf-Yarkoni, A., Ziv, Y., Shabat-Simon, M., Gersner, R., Zangen, A., et al. (2009). Vaccination as a novel approach for treating depressive behavior. Biological Psychiatry, 65(4), 283–288. https://doi.org/10.1016/j.biopsych.2008.07.014.CrossRefPubMed

Li, J., Chen, J., Ma, N., Yan, D., Wang, Y., Zhao, X., et al. (2019). Effects of corticosterone on the expression of mature brain-derived neurotrophic factor (mBDNF) and proBDNF in the hippocampal dentate gyrus. Behavioural Brain Research. https://doi.org/10.1016/j.bbr.2019.03.010.CrossRefPubMed

Murphy, J. A., Sarris, J., & Byrne, G. J. (2017). A review of the conceptualisation and risk factors associated with treatment-resistant depression. Depression Research and Treatment, 2017, 4176825. https://doi.org/10.1155/2017/4176825.CrossRefPubMedPubMedCentral

Murray, C., McGahon, B., McBennett, S., & Lynch, M. (1997). Interleukin-1β inhibits glutamate release in hippocampus of young, but not aged, rats. Neurobiology of Aging, 18(3), 343–348.CrossRef

Murray, C. A., & Lynch, M. A. (1998). Evidence that increased hippocampal expression of the cytokine interleukin-1β is a common trigger for age-and stress-induced impairments in long-term potentiation. Journal of Neuroscience, 18(8), 2974–2981.CrossRef

Muscat, R., & Willner, P. (1992). Suppression of sucrose drinking by chronic mild unpredictable stress: a methodological analysis. Neuroscience & Biobehavioral Reviews, 16(4), 507–517.CrossRef

Nestler, E. J., Barrot, M., DiLeone, R. J., Eisch, A. J., Gold, S. J., & Monteggia, L. M. (2002). Neurobiology of depression. Neuron, 34(1), 13–25.CrossRef

Nestler, E. J., & Carlezon, W. A., Jr. (2006). The mesolimbic dopamine reward circuit in depression. Biological Psychiatry, 59(12), 1151–1159.CrossRef

Nuninga, J. O., Mandl, R. C., Boks, M. P., Bakker, S., Somers, M., Heringa, S. M., et al. (2019). Volume increase in the dentate gyrus after electroconvulsive therapy in depressed patients as measured with 7T. Molecular Psychiatry. https://doi.org/10.1038/s41380-019-0392-6.CrossRefPubMed

Okun, E., Arumugam, T. V., Tang, S. C., Gleichmann, M., Albeck, M., Sredni, B., et al. (2007). The organotellurium compound ammonium trichloro(dioxoethylene-O,O′) tellurate enhances neuronal survival and improves functional outcome in an ischemic stroke model in mice. Journal of Neurochemistry, 102(4), 1232–1241. https://doi.org/10.1111/j.1471-4159.2007.04615.x.CrossRefPubMed

Porsolt, R. D., Anton, G., Blavet, N., & Jalfre, M. (1978). Behavioural despair in rats: a new model sensitive to antidepressant treatments. European Journal of Pharmacology, 47(4), 379–391.CrossRef

Porsolt, R. D., Le Pichon, M., & Jalfre, M. (1977). Depression: a new animal model sensitive to antidepressant treatments. Nature, 266(5604), 730–732.CrossRef

Qian, L., Block, M. L., Wei, S. J., Lin, C. F., Reece, J., Pang, H., et al. (2006). Interleukin-10 protects lipopolysaccharide-induced neurotoxicity in primary midbrain cultures by inhibiting the function of NADPH oxidase. Journal of Pharmacology and Experimental Therapeutics, 319(1), 44–52. https://doi.org/10.1124/jpet.106.106351.CrossRefPubMed

Sanders, A. R., Detera-Wadleigh, S. D., & Gershon, E. S. (1999). Molecular genetics of mood disorders. In D. S. Charney, E. J. Nestler, & E. Bunney (Eds.), neurobiology of mental illness (pp. 299–316). New York: Oxford University Press.

Serra, M., Poddighe, L., Boi, M., Sanna, F., Piludu, M., Sanna, F., et al. (2018). Effect of acute stress on the expression of BDNF, trkB, and PSA-NCAM in the hippocampus of the roman rats: A genetic model of vulnerability/resistance to stress-induced depression. International Journal of Molecular Sciences, 19(12), 3745.CrossRef

Serra, M. P., Poddighe, L., Boi, M., Sanna, F., Piludu, M. A., Corda, M. G., et al. (2017). Expression of BDNF and trkB in the hippocampus of a rat genetic model of vulnerability (Roman low-avoidance) and resistance (Roman high-avoidance) to stress-induced depression. Brain and Behavior, 7(10), e00861.CrossRef

Shelton, R., Claiborne, J., Sidoryk-Wegrzynowicz, M., Reddy, R., Aschner, M., Lewis, D., et al. (2011). Altered expression of genes involved in inflammation and apoptosis in frontal cortex in major depression. Molecular Psychiatry, 16(7), 751.CrossRef

Slevin, J. T., Gerhardt, G. A., Smith, C. D., Gash, D. M., Kryscio, R., & Young, B. (2005). Research on Parkinson disease. Journal of Neurosurgery, 102(2), 401.CrossRef

Sredni, B., Geffen-Aricha, R., Duan, W., Albeck, M., Shalit, F., Lander, H. M., et al. (2007). Multifunctional tellurium molecule protects and restores dopaminergic neurons in Parkinson's disease models. FASEB Journal, 21(8), 1870–1883. https://doi.org/10.1096/fj.06-7500com.CrossRefPubMed

Takamiya, A., Plitman, E., Chung, J. K., Chakravarty, M., Graff-Guerrero, A., Mimura, M., et al. (2019). Acute and long-term effects of electroconvulsive therapy on human dentate gyrus. Neuropsychopharmacology, 44(10), 1805–1811.CrossRef

Taliaz, D., Loya, A., Gersner, R., Haramati, S., Chen, A., & Zangen, A. (2011a). Resilience to chronic stress is mediated by hippocampal brain-derived neurotrophic factor. Journal of Neuroscience, 31(12), 4475–4483.CrossRef

Taliaz, D., Stall, N., Dar, D. E., & Zangen, A. (2010). Knockdown of brain-derived neurotrophic factor in specific brain sites precipitates behaviors associated with depression and reduces neurogenesis. Molecular Psychiatry, 15(1), 80–92. https://doi.org/10.1038/mp.2009.67.CrossRefPubMed

Tanti, A., & Belzung, C. (2013). Neurogenesis along the septo-temporal axis of the hippocampus: Are depression and the action of antidepressants region-specific? Neuroscience, 252, 234–252.CrossRef

Toth, E., Gersner, R., Wilf-Yarkoni, A., Raizel, H., Dar, D. E., Richter-Levin, G., et al. (2008). Age-dependent effects of chronic stress on brain plasticity and depressive behavior. Journal of Neurochemistry, 107(2), 522–532.CrossRef

Ustun, T. B., Ayuso-Mateos, J. L., Chatterji, S., Mathers, C., & Murray, C. J. (2004). Global burden of depressive disorders in the year 2000. British Journal of Psychiatry, 184, 386–392.CrossRef

Wei, I.-H., Chen, K.-T., Tsai, M.-H., Wu, C.-H., Lane, H.-Y., & Huang, C.-C. (2017). Acute amino acid d-serine administration, similar to ketamine, produces antidepressant-like effects through identical mechanisms. Journal of Agricultural and Food Chemistry, 65(49), 10792–10803.CrossRef

Widge, A. S., Malone, D. A., Jr., & Dougherty, D. D. (2018). Closing the loop on deep brain stimulation for treatment-resistant depression. Frontiers in Neuroscience, 12, 175. https://doi.org/10.3389/fnins.2018.00175.CrossRefPubMedPubMedCentral

Zhang, X., Zhang, Z., Sha, W., Xie, C., Xi, G., Zhou, H., et al. (2009). Electroconvulsive therapy increases glial cell-line derived neurotrophic factor (GDNF) serum levels in patients with drug-resistant depression. Psychiatry Research, 170(2–3), 273–275.CrossRef

Titel: A Tellurium-Based Small Immunomodulatory Molecule Ameliorates Depression-Like Behavior in Two Distinct Rat Models
verfasst von: Moshe Hagar
Gersner Roman
Okun Eitan
Barnea-Ygael Noam
Zangen Abrham
Sredni Benjamin
Publikationsdatum: 07.07.2020
Verlag: Springer US
Erschienen in: NeuroMolecular Medicine / Ausgabe 3/2020
Print ISSN: 1535-1084
Elektronische ISSN: 1559-1174
DOI: https://doi.org/10.1007/s12017-020-08603-5

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2020

Alpinia oxyphylla–Schisandra chinensis Herb Pair Alleviates Amyloid-β Induced Cognitive Deficits via PI3K/Akt/Gsk-3β/CREB Pathway

Gnaq Protects PC12 Cells from Oxidative Damage by Activation of Nrf2 and Inhibition of NF-kB

Association of CHRNA5 Gene Variants with Crack Cocaine Addiction

Safflower Yellow Improves Synaptic Plasticity in APP/PS1 Mice by Regulating Microglia Activation Phenotypes and BDNF/TrkB/ERK Signaling Pathway

Downregulation of Microrna-421 Relieves Cerebral Ischemia/Reperfusion Injuries: Involvement of Anti-apoptotic and Antioxidant Activities